Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04488003 · ClinicalTrials.gov registry record · Phase 2
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
A Phase 2 study, sponsored by BioMed Valley Discoveries.
- Terminated
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
NCT04488003 is a Phase 2 study that was terminated before completion, run by BioMed Valley Discoveries. The registered enrollment target is 104 participants.
The verdict
NCT04488003, a Phase 2 study, was terminated before completion, sponsored by BioMed Valley Discoveries.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
Study Summary
This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early clinical data have demonstrated anti-tumor activity with ulixertinib treatment and have identified specific groups of patients for whom additional development is warranted.
Interventions
- DRUG Ulixertinib
- DRUG Physician's Choice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2021-01-07 |
| Est. Completion | 2023-05-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04488003
The ClinicalTrials.gov registry entry for NCT04488003 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BioMed Valley Discoveries, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ulixertinib is the first listed.
NCT04488003 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04488003 about?
NCT04488003 is a clinical study titled "Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations". This BVD-523-ABC study builds on the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early c...
What is the current status of trial NCT04488003?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2021-01-07. Estimated completion is 2023-05-23.
What interventions are being tested in trial NCT04488003?
The interventions under investigation include: Ulixertinib (DRUG), Physician's Choice (DRUG).
Who is sponsoring clinical trial NCT04488003?
This trial is sponsored by BioMed Valley Discoveries, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.